Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.

The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.

In this video, Philip J. Mease, MD, discusses the potential for the development of a T-cell engaging antibody.